

INNOSPEC INC.  
Form 10-Q  
May 07, 2014  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 10-Q**

x **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2014**

**or**

.. **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from                      to**

**Commission file number 1-13879**

**INNOSPEC INC.**

**(Exact name of registrant as specified in its charter)**

<p><b>DELAWARE</b>                  (State or other jurisdiction of                  incorporation or organization)</p> <p><b>8310 South Valley Highway</b>   <b>Suite 350</b>   <b>Englewood</b>   <b>Colorado</b>                  (Address of principal executive offices)  <b>Registrant's telephone number, including area code: (303) 792 5554</b></p>	<p><b>98-0181725</b>                  (I.R.S. Employer                  Identification No.)</p> <p><b>80112</b>                  (Zip Code)</p>
--	---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer <input type="checkbox"/>	Accelerated filer <input checked="" type="checkbox"/>
Non-accelerated filer <input type="checkbox"/> (Do not check if a smaller reporting company)	Smaller reporting company <input type="checkbox"/>

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class	Outstanding as of April 30, 2014
Common Stock, par value \$0.01	24,386,463



**Table of Contents**

**TABLE OF CONTENTS**

<b><u>PART I FINANCIAL INFORMATION</u></b>	4
Item 1 <b><u>Financial Statements</u></b>	4
<b><u>Consolidated Statements of Income</u></b>	4
<b><u>Consolidated Statements of Comprehensive Income</u></b>	5
<b><u>Consolidated Balance Sheets</u></b>	6
<b><u>Consolidated Balance Sheets (continued)</u></b>	7
<b><u>Consolidated Statements of Cash Flows</u></b>	8
<b><u>Consolidated Statements of Stockholders' Equity</u></b>	9
<b><u>Notes to the Unaudited Interim Consolidated Financial Statements</u></b>	10
Item 2 <b><u>Management's Discussion and Analysis of Financial Condition and Results of Operations for the Three Months Ended March 31, 2014</u></b>	23
<b><u>Critical Accounting Estimates</u></b>	23
<b><u>Results of Operations</u></b>	23
<b><u>Liquidity and Financial Condition</u></b>	27
Item 3 <b><u>Quantitative and Qualitative Disclosures about Market Risk</u></b>	28
Item 4 <b><u>Controls and Procedures</u></b>	29
<b><u>PART II OTHER INFORMATION</u></b>	29
Item 1 <b><u>Legal Proceedings</u></b>	29
Item 1A <b><u>Risk Factors</u></b>	30
Item 2 <b><u>Unregistered Sales of Equity Securities and Use of Proceeds</u></b>	30
Item 3 <b><u>Defaults Upon Senior Securities</u></b>	30
Item 4 <b><u>Mine Safety Disclosures</u></b>	30
Item 5 <b><u>Other Information</u></b>	30
Item 6 <b><u>Exhibits</u></b>	30
<b><u>SIGNATURES</u></b>	32

**Table of Contents**

**CAUTIONARY STATEMENT RELATIVE TO FORWARD-LOOKING STATEMENTS**

This Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Such forward-looking statements include statements (covered by words like expects, estimates, anticipates, may, believes or similar words or expressions), for example, which relate to operating performance, events or developments that we expect or anticipate will or may occur in the future (including, without limitation, any of the Company's guidance in respect of sales, gross margins, pension liabilities and charges, net income, growth potential and other measures of financial performance). Although forward-looking statements are believed by management to be reasonable when made, they are subject to certain risks, uncertainties and assumptions, and our actual performance or results may differ materially from these forward-looking statements. Additional information regarding risks, uncertainties and assumptions relating to the Company and affecting our business operations and prospects are described in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and other reports filed with the U.S. Securities and Exchange Commission. You are urged to review our discussion of risks and uncertainties that could cause actual results to differ from forward-looking statements under the heading Risk Factors in such reports. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

**Table of Contents****PART I FINANCIAL INFORMATION****Item 1 Financial Statements****INNOSPEC INC. AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF INCOME****(Unaudited)**

<b>(in millions, except share and per share data)</b>	<b>Three Months Ended March 31</b>	
	<b>2014</b>	<b>2013</b>
Net sales	\$ 220.7	\$ 199.4
Cost of goods sold	(155.0)	(135.6)
Gross profit	65.7	63.8
Operating expenses:		
Selling, general and administrative	(41.8)	(35.7)
Research and development	(5.7)	(5.6)
Restructuring charge	(0.2)	0.0
Impairment of Octane Additives segment goodwill	0.0	(0.3)
Total operating expenses	(47.7)	(41.6)
Operating income	18.0	22.2
Other net income/(expense)	1.9	1.0
Interest expense	(1.0)	(0.4)
Interest income	0.1	0.1
Income before income taxes	19.0	22.9
Income taxes	(2.1)	(4.9)
Net income	\$ 16.9	\$ 18.0
Earnings per share:		
Basic	\$ 0.69	\$ 0.77
Diluted	\$ 0.69	\$ 0.75
Weighted average shares outstanding (in thousands):		
Basic	24,362	23,404
Diluted	24,635	24,015

The accompanying notes are an integral part of these unaudited interim consolidated financial statements.

Table of Contents

**INNOSPEC INC. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

(Unaudited)

(in millions)	<b>Three Months Ended March 31</b>	
	<b>2014</b>	<b>2013</b>
Net income	\$ 16.9	\$ 18.0
Other comprehensive income/(loss):		
Changes in cumulative translation adjustment	(1.2)	(3.6)
Changes in unrealized gains/(losses) on derivative instruments, net of tax of \$0.0 and \$0.0, respectively	0.0	(0.1)
Amortization of prior service credit, net of tax of \$0.1 and \$0.1, respectively	(0.3)	(0.2)
Amortization of actuarial net losses, net of tax of \$(0.3) and \$(0.4), respectively	1.1	1.3
Total other comprehensive income/(loss)	(0.4)	(2.6)
Total comprehensive income	\$ 16.5	\$ 15.4

The accompanying notes are an integral part of these unaudited interim consolidated financial statements.



**Table of Contents****INNOSPEC INC. AND SUBSIDIARIES****CONSOLIDATED BALANCE SHEETS**

<b>(in millions, except share and per share data)</b>	<b>March 31, 2014 (Unaudited)</b>	<b>December 31, 2013</b>
<b><u>Assets</u></b>		
Current assets:		
Cash and cash equivalents	\$ 90.1	\$ 80.2
Short-term investments	5.8	6.6
Trade and other accounts receivable (less allowances of \$2.0 and \$2.0, respectively)	122.0	135.8
Inventories (less allowances of \$9.1 and \$9.5, respectively):		
Finished goods	101.7	95.3
Work in progress	2.7	1.9
Raw materials	55.8	61.7
Total inventories	160.2	158.9
Current portion of deferred tax assets	8.7	8.7
Prepaid expenses	4.4	5.8
Prepaid income taxes	3.4	11.4
Total current assets	394.6	407.4
Property, plant and equipment:		
Gross cost	157.5	175.1
Less accumulated depreciation	(97.4)	(114.7)
Net property, plant and equipment	60.1	60.4
Goodwill	187.9	187.9
Other intangible assets	124.0	126.8
Deferred finance costs	1.6	1.8
Deferred tax assets, net of current portion	8.0	8.6
Other non-current assets	1.4	1.8
Total assets	\$ 777.6	\$ 794.7

The accompanying notes are an integral part of these unaudited interim consolidated financial statements.

**Table of Contents**

**INNOSPEC INC. AND SUBSIDIARIES**  
**CONSOLIDATED BALANCE SHEETS (Continued)**

(in millions, except share and per share data)	March 31, 2014 (Unaudited)	December 31, 2013
<u>Liabilities and Stockholders' Equity</u>		
Current liabilities:		
Accounts payable	\$ 53.9	\$ 63.3
Accrued liabilities	61.8	73.5
Current portion of long-term debt	5.4	5.3
Current portion of plant closure provisions	5.4	6.2
Current portion of unrecognized tax benefits	0.0	6.8
Current portion of deferred tax liabilities	0.2	0.2
Current portion of deferred income	0.3	0.3
Total current liabilities	127.0	155.6
Long-term debt, net of current portion	134.3	142.7
Plant closure provisions, net of current portion	27.3	26.2
Unrecognized tax benefits, net of current portion	9.0	6.2
Deferred tax liabilities, net of current portion	11.1	9.5
Pension liabilities	36.1	39.0
Acquisition-related contingent consideration	4.7	4.6
Other non-current liabilities	0.1	0.3
Deferred income, net of current portion	1.2	1.2
Stockholders' equity:		
Common stock, \$0.01 par value, authorized 40,000,000 shares, issued 29,554,500 shares	0.3	0.3
Additional paid-in capital	309.3	308.8
Treasury stock (5,168,037 and 5,207,947 shares at cost, respectively)	(72.9)	(73.3)
Retained earnings	344.4	327.5
Accumulated other comprehensive loss	(154.3)	(153.9)
Total stockholders' equity	426.8	409.4
Total liabilities and stockholders' equity	\$ 777.6	\$ 794.7

The accompanying notes are an integral part of these unaudited interim consolidated financial statements.

Table of Contents

**INNOSPEC INC. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**

(Unaudited)

(in millions)	<b>Three Months Ended</b>	
	<b>March 31</b>	
	<b>2014</b>	<b>2013</b>
<b><u>Cash Flows from Operating Activities</u></b>		
Net income	\$ 16.9	\$ 18.0
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	7.4	4.5
Impairment of Octane Additives segment goodwill	0.0	0.3
Deferred taxes	0.4	(0.2)
Excess tax benefit from stock-based payment arrangements	(0.2)	(1.5)
Cash contributions to defined benefit pension plans	(2.9)	(2.8)
Non-cash expense of defined benefit pension plans	1.0	0.9
Stock option compensation	0.6	0.7
Changes in assets and liabilities, net of effects of acquired and divested companies:		
Trade and other accounts receivable	14.2	16.8
Inventories	(1.1)	(4.6)
Prepaid expenses	1.5	(0.4)
Accounts payable and accrued liabilities	(21.4)	(13.8)
Accrued income taxes	8.0	(0.6)
Plant closure provisions	0.3	0.1
Unrecognized tax benefits	(4.0)	(0.4)
Other non-current assets and liabilities	0.2	0.9
Net cash provided by operating activities	20.9	17.9
<b><u>Cash Flows from Investing Activities</u></b>		
Capital expenditures	(2.4)	(2.2)
Internally developed software and other costs	(1.5)	(2.1)
Proceeds on disposal of property, plant and equipment	0.1	0.0
Purchase of short-term investments	(1.2)	(1.1)
Sale of short-term investments	2.0	0.9
Net cash provided by/(used in) investing activities	(3.0)	(4.5)
<b><u>Cash Flows from Financing Activities</u></b>		
Proceeds from revolving credit facility	0.0	21.0
Repayments of revolving credit facility	(8.0)	(14.0)
Repayments of term loans	(0.3)	0.0
Excess tax benefit from stock-based payment arrangements	0.2	1.5
Issue of treasury stock	0.3	0.4
Repurchase of common stock	(0.2)	(1.3)

Edgar Filing: INNOSPEC INC. - Form 10-Q

Net cash provided by/(used in) financing activities	(8.0)	7.6
Effect of foreign currency exchange rate changes on cash	0.0	(0.2)
Net change in cash and cash equivalents	9.9	20.8
Cash and cash equivalents at beginning of period	80.2	22.4
Cash and cash equivalents at end of period	\$ 90.1	\$ 43.2

Amortization of deferred finance costs of \$0.2 million (2013 \$0.1 million) are included in depreciation and amortization in the cash flow statement but in interest expense in the income statement.

The accompanying notes are an integral part of these unaudited interim consolidated financial statements.

Table of Contents

**INNOSPEC INC. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY**

(Unaudited)

(in millions)	Common Stock	Additional Paid-In Capital	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Loss	Total Stockholders Equity
Balance at December 31, 2013	\$ 0.3	\$ 308.8	\$ (73.3)	\$ 327.5	\$ (153.9)	\$ 409.4
Net income				16.9		16.9
Changes in cumulative translation adjustment					(1.2)	(1.2)
Treasury stock re-issued		(0.3)	0.6			0.3
Treasury stock repurchased			(0.2)			(0.2)
Excess tax benefit from stock-based payment arrangements		0.2				0.2
Stock option compensation		0.6				0.6
Amortization of prior service credit, net of tax					(0.3)	(0.3)
Amortization of actuarial net losses, net of tax					1.1	1.1
Balance at March 31, 2014	\$ 0.3	\$ 309.3	\$ (72.9)	\$ 344.4	\$ (154.3)	\$ 426.8

The accompanying notes are an integral part of these unaudited interim consolidated financial statements.

**Table of Contents**

**INNOSPEC INC. AND SUBSIDIARIES**

**NOTES TO THE UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

***NOTE 1 BASIS OF PRESENTATION***

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934. Accordingly, they do not include all the information and notes necessary for a comprehensive presentation of financial position, results of operations and cash flows.

It is our opinion, however, that all adjustments (consisting of normal, recurring adjustments, unless otherwise disclosed) have been made which are necessary for the financial statements to be fairly stated. These financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K filed on February 13, 2014.

The results for the interim period covered by this report are not necessarily indicative of the results to be expected for the full year.

When we use the terms the Corporation, Company, Registrant, we, us and our, we are referring to Innospec Inc. and its consolidated subsidiaries (Innospec) unless otherwise indicated or the context otherwise requires.

***NOTE 2 SEGMENTAL REPORTING***

Innospec divides its business into three segments for management and reporting purposes: Fuel Specialties, Performance Chemicals and Octane Additives. The Fuel Specialties and Performance Chemicals segments operate in markets where we actively seek growth opportunities although their ultimate customers are different. The Octane Additives segment is generally characterized by volatile and declining demand.

**Table of Contents**

The Company evaluates the performance of its segments based on operating income. The following table analyzes sales and other financial information by the Company's reportable segments:

(in millions)	Three Months Ended March 31	
	2014	2013
<b>Net sales:</b>		
Fuel Specialties	\$ 164.2	\$ 140.0
Performance Chemicals	56.1	47.8
Octane Additives	0.4	11.6
	\$ 220.7	\$ 199.4
<b>Gross profit:</b>		
Fuel Specialties	\$ 52.0	\$ 47.0
Performance Chemicals	13.6	10.5
Octane Additives	0.1	6.3
	\$ 65.7	\$ 63.8
<b>Operating income:</b>		
Fuel Specialties	\$ 25.8	\$ 24.9
Performance Chemicals	6.5	5.0
Octane Additives	(1.2)	4.8
Pension credit/(charge)	(0.8)	(0.7)
Corporate costs	(12.1)	(11.5)
Restructuring charge	(0.2)	0.0
Impairment of Octane Additives segment goodwill	0.0	(0.3)
<b>Total operating income</b>	<b>\$ 18.0</b>	<b>\$ 22.2</b>

The pension credit/(charge) relates to the United Kingdom defined benefit pension plan which is closed to future service accrual. The charges related to our other much smaller pension arrangements in the U.S. and overseas are included in the segment and income statement captions consistent with the related employees' costs.

The following table presents a summary of the depreciation and amortization charges incurred by the Company's reportable segments:

(in millions)	Three Months Ended March 31	
	2014	2013
<b>Depreciation:</b>		
Fuel Specialties	\$ 1.2	\$ 0.6
Performance Chemicals	0.9	0.9

Edgar Filing: INNOSPEC INC. - Form 10-Q

Octane Additives	0.1	0.2
Corporate	0.6	0.6
	\$ 2.8	\$ 2.3
<b>Amortization:</b>		
Fuel Specialties	\$ 2.2	\$ 1.6
Performance Chemicals	1.3	0.4
Octane Additives	0.0	0.1
Corporate	0.9	0.0
	\$ 4.4	\$ 2.1



**Table of Contents****NOTE 3 EARNINGS PER SHARE**

Basic earnings per share is based on the weighted average number of common shares outstanding during the period. Diluted earnings per share includes the effect of options that are dilutive and outstanding during the period. Per share amounts are computed as follows:

	<b>Three Months Ended March 31</b>	
	<b>2014</b>	<b>2013</b>
<b>Numerator (in millions):</b>		
Net income available to common stockholders	\$ 16.9	\$ 18.0
<b>Denominator (in thousands):</b>		
Weighted average common shares outstanding	24,362	23,404
Dilutive effect of stock options and awards	273	611
Denominator for diluted earnings per share	24,635	24,015
<b>Net income per share, basic:</b>	<b>\$ 0.69</b>	<b>\$ 0.77</b>
<b>Net income per share, diluted:</b>	<b>\$ 0.69</b>	<b>\$ 0.75</b>

In the three months ended March 31, 2014 and 2013, the average number of anti-dilutive options excluded from the calculation of diluted earnings per share were 8,049 and 10,527, respectively.

**NOTE 4 GOODWILL**

The following table summarizes the goodwill movement year on year:

	<b>Three Months Ended March 31</b>	
<b>(in millions)</b>	<b>2014</b>	<b>2013</b>
<b>At January 1:</b>		
Gross cost <sup>(1)</sup>	\$ 424.4	\$ 384.2
Accumulated impairment losses	(236.5)	(235.2)
Net book amount	187.9	149.0
Exchange effect	0.0	(0.1)
Impairment losses	0.0	(0.3)
<b>At March 31:</b>		
Gross cost <sup>(1)</sup>	424.4	384.1

Accumulated impairment losses	(236.5)	(235.5)
Net book amount	\$ 187.9	\$ 148.6

(1) Gross cost for 2014 and 2013 is net of \$298.5 million of historical accumulated amortization.

***The Bachman Group Companies Acquisition***

On November 4, 2013, the Company acquired 100% of the voting equity interests in Bachman Services, Inc., Specialty Intermediates, Inc., Bachman Production Specialties, Inc. and Bachman Drilling & Production Specialties, Inc. (collectively *Bachman*). *Bachman* provide chemicals and services to the oil and gas industry and are based in Oklahoma City, Oklahoma. We purchased *Bachman* for a cash consideration of \$45.8 million and by the issuance of 319,953 shares of unregistered Innospec Inc. common stock to the previous owners with a fair value of approximately \$15 million, based on the Innospec share price on the closing date. We acquired the businesses in order to move us towards critical mass, and bring both good technology and market positioning in the oilfield specialties sector which forms part of our Fuel Specialties segment.

**Table of Contents**

The following table summarizes the calculations of the total purchase price and the estimated allocation of the purchase price to the assets acquired and liabilities assumed for Bachman. The purchase price allocation is not yet complete as we are in the process of finalising the valuation of the assets acquired. We expect to complete the valuations in the second quarter of 2014 following agreement with the previous owners. Final determination of the fair values may result in adjustments to the amounts presented below:

<b>(in millions)</b>	<b>Bachman</b>
Other intangible assets	\$ 25.9
Goodwill	22.9
Deferred tax on intangibles	(7.6)
Other net assets acquired, excluding cash of \$2.0m	17.6
<b>Purchase price, net of cash acquired</b>	<b>\$ 58.8</b>

Bachman, and the associated goodwill, are included within our Fuel Specialties segment for management and reporting purposes.

**NOTE 5 OTHER INTANGIBLE ASSETS**

The following table summarizes the other intangible assets movement year on year:

<b>(in millions)</b>	<b>Three Months Ended</b>	
	<b>March 31</b>	
	<b>2014</b>	<b>2013</b>
Gross cost at January 1	\$ 175.5	\$ 106.2
Capitalization of internally developed software and other costs	1.5	2.1
Exchange effect	0.0	0.0
Gross cost at March 31	177.0	108.3
Accumulated amortization at January 1	(48.7)	(37.6)
Amortization expense	(4.4)	(2.1)
Exchange effect	0.1	(0.1)
Accumulated amortization at March 31	(53.0)	(39.8)
<b>Net book amount at March 31</b>	<b>\$ 124.0</b>	<b>\$ 68.5</b>

**Capitalization of internally developed software and other costs**

We are continuing with the implementation of a new, company-wide, information system platform. At March 31, 2014, we had capitalized \$20.1 million (2013 \$12.2 million) in relation to this internally developed software.

**Amortization expense**

<b>(in millions)</b>	<b>Three Months Ended</b>	
	<b>March 31</b>	
	<b>2014</b>	<b>2013</b>
Product rights	\$ (1.0)	\$ 0.0
Brand names	(0.1)	0.0
Technology	(0.6)	(0.5)
Customer relationships	(1.3)	(0.9)
Patents	(0.1)	(0.1)
Internally developed software	(0.9)	0.0
Non-compete agreements	(0.2)	(0.2)
Marketing related	(0.2)	(0.4)
<b>Total</b>	<b>\$ (4.4)</b>	<b>\$ (2.1)</b>

**Table of Contents****NOTE 6 PENSION PLANS**

The Company maintains a defined benefit pension plan (the Plan ) covering a number of its current and former employees in the United Kingdom, although it does also have other much smaller pension arrangements in the U.S. and overseas. The Plan is closed to future service accrual but has a large number of deferred and current pensioners.

(in millions)	Three Months Ended March 31	
	2014	2013
<b>Plan net pension credit/(charge):</b>		
Service cost	\$ (0.4)	\$ (0.4)
Interest cost on projected benefit obligation	(8.7)	(7.9)
Expected return on plan assets	9.3	9.0
Amortization of prior service credit	0.4	0.3
Amortization of actuarial net losses	(1.4)	(1.7)
	\$ (0.8)	\$ (0.7)

The amortization of prior service credit and actuarial net losses is a reclassification out of accumulated other comprehensive income/(loss) into selling, general and administrative expenses.

**NOTE 7 INCOME TAXES**

A roll-forward of unrecognized tax benefits and associated accrued interest and penalties is as follows:

(in millions)	Interest and Penalties	Unrecognized Tax	
		Benefits	Total
Opening balance at January 1, 2014	\$ 1.1	\$ 11.9	\$ 13.0
Reductions for tax positions of prior periods	(0.4)	(3.6)	(4.0)
Closing balance at March 31, 2014	0.7	8.3	9.0
Current	0.0	0.0	0.0
Non-current	\$ 0.7	\$ 8.3	\$ 9.0

All of the unrecognized tax benefits, interest and penalties, would impact our effective tax rate if recognized.

We recognize accrued interest and penalties associated with uncertain tax positions as part of income taxes in our consolidated statements of income.

The Company or one of its subsidiaries files income tax returns with the U.S. federal government, and various state and foreign jurisdictions. As previously disclosed, as at December 31, 2013, the Company and its U.S. subsidiaries were subject to tax audits in the U.S.. On March 6, 2014, the federal income tax examination by the IRS for 2009 was

effectively settled. The additional tax cost was nominal and resulted in a reduction of \$3.6 million in unrecognized tax benefits and a reduction of \$0.4 million in associated interest and penalties in the first quarter of 2014.

The Company and its U.S. subsidiaries remain open to examination by the IRS for years 2010 onwards. The Company's subsidiaries in foreign tax jurisdictions are open to examination including France (2012 onwards), Germany (2010 onwards), Switzerland (2012 onwards) and the United Kingdom (2012 onwards).

**Table of Contents**

The Company is in a position to control whether or not to repatriate foreign earnings and we intend to permanently reinvest earnings overseas to fund overseas subsidiaries. No taxes have been provided for on the unremitted earnings of our overseas subsidiaries as any tax basis differences relating to investments in these overseas subsidiaries are considered to be permanent in duration. The amount of unremitted earnings at December 31, 2013 and 2012 was approximately \$605 million and \$717 million, respectively. If these earnings are remitted, additional taxes could result after offsetting foreign income taxes paid although the calculation of the additional taxes is not practical at this time.

**NOTE 8 LONG-TERM DEBT**

Long-term debt consists of the following:

<b>(in millions)</b>	<b>March 31, 2014</b>	<b>December 31, 2013</b>
Revolving credit facility	\$ 134.0	\$ 142.0
Promissory note	5.0	5.0
Other long-term debt	0.7	1.0
	139.7	148.0
Less current portion	(5.4)	(5.3)
	\$ 134.3	\$ 142.7

The credit facility provides for borrowings by us of up to \$180 million until it expires on December 14, 2016 and may be drawn down in full in the U.S.. In addition, the Company can request an additional amount of up to \$20 million to be committed by the lenders.

**NOTE 9 PLANT CLOSURE PROVISIONS**

The liability for estimated closure costs of Innospec's manufacturing facilities includes costs for decontamination and environmental remediation activities ( remediation ). The principal site giving rise to remediation liabilities is the manufacturing site at Ellesmere Port in the United Kingdom. There are also remediation liabilities on a much smaller scale in respect of our other manufacturing sites in the U.S. and Europe.

Movements in the provisions for the three months ended March 31 are summarized as follows:

<b>(in millions)</b>	<b>2014</b>			<b>2013</b>
	<b>Severance</b>	<b>Remediation</b>	<b>Total</b>	<b>Total</b>
Total at January 1	\$ 1.0	\$ 31.4	\$ 32.4	\$ 30.4
Charge for the period	0.0	0.7	0.7	0.6
Utilized in the period	0.0	(0.4)	(0.4)	(0.6)
Exchange effect	0.0	0.0	0.0	0.0
Total at March 31	1.0	31.7	32.7	30.4
Due within one year	0.0	(5.4)	(5.4)	(4.2)

Due after one year	\$ 1.0	\$	26.3	\$ 27.3	\$ 26.2
--------------------	--------	----	------	---------	---------



**Table of Contents**

Amounts due within one year refer to provisions where expenditure is expected to arise within one year of the balance sheet date. Severance charges are recognized in the income statement as restructuring costs along with other restructuring costs. Remediation costs are recognized in cost of goods sold.

**Remediation**

The remediation provision represents the Company's liability for environmental liabilities and asset retirement obligations. The charge for the period represents the accretion expense recognized in the first three months of 2014.

We recognize environmental liabilities when they are probable and costs can be reasonably estimated, and asset retirement obligations when there is a legal obligation and costs can be reasonably estimated. The Company has to anticipate the program of work required and the associated future expected costs, and comply with environmental legislation in the countries in which it operates or has operated in. The Company views the costs of vacating our Ellesmere Port site as contingent upon if and when it vacates the site because there is no present intention to do so. The Company has further determined that, due to the uncertain product life of TEL particularly in the market for aviation gasoline and other products being manufactured on the site, there are uncertainties as to the probability and timing of the expected costs. Such uncertainties have been considered in estimating the provision.

***NOTE 10 FAIR VALUE MEASUREMENTS***

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes a mid-market pricing convention for valuing the majority of its assets and liabilities measured and reported at fair value. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated or generally unobservable. The Company primarily applies the market approach for recurring fair value measurements and endeavors to utilize the best available information. Accordingly, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The Company is able to classify fair value balances based on the observability of those inputs. The Company gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels. In the first three months of 2014, the Company evaluated the fair value hierarchy levels assigned to its assets and liabilities, and concluded that there should be no transfers into or out of Levels 1, 2 and 3.

**Table of Contents**

The following table presents the carrying amount and fair values of the Company's assets and liabilities measured on a recurring basis:

(in millions)	March 31, 2014		December 31, 2013	
	Carrying Amount	Fair Value	Carrying Amount	Fair Value
<b>Assets</b>				
<b>Non-derivatives:</b>				
Cash and cash equivalents	\$ 90.1	\$ 90.1	\$ 80.2	\$ 80.2
Short-term investments	5.8	5.8	6.6	6.6
<b>Derivatives (Level 1 measurement):</b>				
Other non-current assets:				
Foreign currency forward exchange contracts	0.7	0.7	1.0	1.0
<b>Liabilities</b>				
<b>Non-derivatives:</b>				
Long-term debt (including current portion)	\$ 139.7	\$ 139.7	\$ 148.0	\$ 148.0
<b>Non-financial liabilities (Level 3 measurement):</b>				
Stock equivalent units	7.1	7.1	12.1	12.1
Acquisition-related contingent consideration	4.7	4.7	4.6	4.6

Foreign currency forward exchange contracts primarily relate to contracts entered into to hedge future known transactions or hedge balance sheet net cash positions. The movements in the carrying amounts and fair values of these contracts are largely due to changes in exchange rates against the U.S. dollar.

**NOTE 11 DERIVATIVE INSTRUMENTS AND RISK MANAGEMENT**

The Company has limited involvement with derivative instruments and does not trade them. The Company does use derivatives to manage certain interest rate, foreign currency exchange rate and raw material cost exposures, as the need arises. As at March 31, 2014 and December 31, 2013 the Company did not hold any interest rate or raw material derivatives.

The Company enters into various foreign currency forward exchange contracts to minimize currency exchange rate exposure from expected future cash flows. As at March 31, 2014 the contracts have maturity dates of up to one year at the date of inception. These foreign currency forward exchange contracts have not been designated as hedging instruments, and their impact on the income statement for the first three months of 2014 was \$0.0 million.

The Company sells a range of Fuel Specialties, Performance Chemicals and Octane Additives products to major oil refineries, oil & gas exploration and production companies and chemical companies throughout the world. Credit limits, ongoing credit evaluation and account monitoring procedures are intended to minimize bad debt risk. Collateral is not generally required.

---

**Table of Contents**

***NOTE 12 COMMITMENTS AND CONTINGENCIES***

**Jalal Bezee Mejel Al-Gaood & Partner litigation**

On September 19, 2012, a claim was filed in the High Court of Justice in the United Kingdom by Jalal Bezee Mejel Al-Gaood & Partner and Future Agencies Company Limited (collectively "JAG") against the Company, Innospec Limited and a former employee of Innospec Limited. The Company believes JAG was the former Iraq distributor for Afton Chemicals Limited, a subsidiary of NewMarket Corporation, from at least 2005 until termination of that relationship in 2010. The stated claim, inclusive of costs and expenses, is for up to \$42.3 million and relates to alleged loss of profits for JAG's business in Iraq between 2004 and 2010. The Company believes that the allegations in the JAG claim are without merit and intends to defend vigorously its interests.

**Other legal matters**

While we are involved from time to time in claims and legal proceedings that result from, and are incidental to, the conduct of our business including business and commercial litigation, employee and product liability claims, there are no other material pending legal proceedings to which the Company or any of its subsidiaries is a party, or of which any of their property is subject. It is possible, however, that an adverse resolution of an unexpectedly large number of such individual claims or proceedings could in the aggregate have a material adverse effect on results of operations for a particular year or quarter.

**Guarantees**

The Company and certain of the Company's consolidated subsidiaries are contingently liable for certain obligations of affiliated companies primarily in the form of guarantees of debt and performance under contracts entered into as a normal business practice. This includes guarantees of non-U.S. excise taxes and customs duties. As at March 31, 2014, such contingent liabilities which are not recognized as liabilities in the consolidated financial statements amounted to \$4.7 million.

Under the terms of the guarantee arrangements, generally the Company would be required to perform should the affiliated company fail to fulfil its obligations under the arrangements. In some cases, the guarantee arrangements have recourse provisions that would enable the Company to recover any payments made under the terms of the guarantees from securities held of the guaranteed parties' assets.

The Company and its affiliates have numerous long-term sales and purchase commitments in their various business activities, which are expected to be fulfilled with no adverse consequences material to the Company.

***NOTE 13 STOCKHOLDERS EQUITY AND STOCK-BASED COMPENSATION PLANS***

At March 31, 2014, the Company had authorized common stock of 40,000,000 shares (December 31, 2013 40,000,000). Issued shares at March 31, 2014, were 29,554,500 (December 31, 2013 29,554,500) and treasury stock amounted to 5,168,037 shares (December 31, 2013 5,207,947).

The Company grants stock options and stock equivalent units ("SEUs") from time to time as a long-term performance incentive. In certain cases the grants are subject to performance conditions such as the Company's stock price. Where performance conditions apply the Monte Carlo simulation model is used to determine the fair values. Otherwise the Black-Scholes model is used to determine the fair values.



**Table of Contents****Stock option plans**

The Company has four active stock option plans, two of which provide for the grant of stock options to employees and one provides for the grant of stock options to non-employee directors. The fourth plan is a savings plan which provides for the grant of stock options to all Company employees provided they commit to make regular savings over a pre-defined period which can then be used to purchase common stock upon vesting of the options. The stock options have discrete vesting periods which range from 24 months to 6 years and in all cases stock options granted expire within 10 years of the date of grant. All grants are at the sole discretion of the Compensation Committee of the Board of Directors. Grants may be priced at market value or at a premium or discount (including at no cost). The aggregate number of shares of common stock reserved for issuance which can be granted under the plans is 2,640,000.

The following table summarizes the transactions of the Company's stock option plans for the three months ended March 31, 2014:

	<b>Number of Options</b>	<b>Weighted Average Exercise Price</b>	<b>Weighted Average Grant-Date Fair Value</b>
Outstanding at December 31, 2013	447,390	\$ 7.33	
Granted at discount	55,176	\$ 0.00	\$ 33.44
at market value	21,542	\$ 46.03	\$ 14.18
Exercised	(43,770)	\$ 6.16	
Forfeited	(2,844)	\$ 10.36	
 Outstanding at March 31, 2014	 477,494	 \$ 8.32	

At March 31, 2014, there were 158,829 stock options that were exercisable, of which 67,001 had performance conditions attached.

The Company's policy is to issue shares from treasury stock to holders of stock options who exercise those options, but if sufficient treasury stock is not available, the Company will issue previously unissued shares of stock to holders of stock options who exercise options.

The total compensation cost for the first three months of 2014 was \$0.6 million (2013 \$0.7 million). The total intrinsic value of options exercised in the first three months of 2014 was \$0.5 million (2013 \$1.9 million).

The total compensation cost related to non-vested stock options not yet recognized at March 31, 2014 was \$3.8 million and this cost is expected to be recognized over the weighted-average period of 2.31 years.

**Stock equivalent units**

SEUs have discrete vesting periods which range from 11 months to 4 years and in all cases SEUs granted expire within 10 years of the date of grant. Grants may be priced at market value or at a premium or discount (including at no cost). There is no limit to the number of SEUs that can be granted. The liability for SEUs is located in accrued liabilities in the consolidated balance sheets until they are cash settled.



**Table of Contents**

The following table summarizes the transactions of the Company's SEUs for the three months ended March 31, 2014:

	<b>Number of SEUs</b>	<b>Weighted Average Exercise Price</b>	<b>Weighted Average Grant-Date Fair Value</b>
Outstanding at December 31, 2013	403,262	\$ 3.64	
Granted at discount	48,213	\$ 0.00	\$ 33.04
at market value	7,147	\$ 46.03	\$ 14.18
Exercised	(141,600)	\$ 5.52	
Forfeited	(3,847)	\$ 9.60	
Outstanding at March 31, 2014	313,175	\$ 3.21	

At March 31, 2014 there were 100,593 SEUs that are exercisable, of which 88,645 had performance conditions attached.

The charges for SEUs are spread over the life of the award subject to a revaluation to fair value each quarter. The revaluation may result in a charge or a credit to the income statement in the quarter dependent upon our share price and other performance criteria.

The total compensation cost for the first three months of 2014 was \$0.6 million (2013 \$3.7 million). The total intrinsic value of SEUs exercised in the first three months of 2014 was \$3.0 million (2013 \$1.2 million).

The weighted-average remaining vesting period of non-vested SEUs is 1.72 years.

**Long-term incentive plan**

In the first quarter of 2014, Innospec granted a long-term incentive plan to reward selected executives with a bonus for delivering exceptional performance. One of the elements of the plan is payable if the Innospec share performance matches or out-performs that of competitors, as measured by the Russell 2000 Index, over the performance period January 1, 2014 to December 31, 2016. The maximum bonus payable under this element of the plan is \$3 million. Under GAAP this element is determined to be share-based compensation and as such the fair value of these liability cash-settled stock appreciation rights is calculated on a quarterly basis. The fair value is calculated using a Monte Carlo model and is summarized as follows:

<b>(in millions)</b>	<b>2014</b>
Balance at January 1	\$ 0.0
Compensation charge for the period	0.1
Balance at March 31	\$ 0.1

The following assumptions were used in the Monte Carlo model at March 31, 2014:

	<b>2014</b>
Dividend yield	1.11%
Volatility of Innospec's share price	36.0%
Risk free interest rate	0.90%



**Table of Contents****NOTE 14 RECLASSIFICATIONS OUT OF ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS)**

Reclassifications out of accumulated other comprehensive loss for the first three months of 2014 were:

(in millions)	Amount Reclassified from AOCL	Affected Line Item in the Statement where Net Income is Presented
<b>Details about AOCL Components</b>		
<b>Defined benefit pension plan items:</b>		
Amortization of prior service credit	\$ (0.4)	See <sup>(1)</sup> below
Amortization of actuarial net losses	1.4	See <sup>(1)</sup> below
	1.0	Total before tax
	(0.2)	Income tax expense
	0.8	Net of tax
<b>Total reclassifications</b>	<b>\$ 0.8</b>	<b>Net of tax</b>

<sup>(1)</sup> These items are included in the computation of net periodic pension cost. See Note 6 for additional information. Changes in accumulated other comprehensive loss for the first three months of 2014, net of tax, were:

(in millions)	Defined Benefit Pension Plan Items	Cumulative Translation Adjustments	Total
Balance at December 31, 2013	\$ (120.2)	\$ (33.7)	\$ (153.9)
Other comprehensive income/(loss) before reclassifications	0.0	(1.2)	(1.2)
Amounts reclassified from AOCL	0.8	0.0	0.8
Total other comprehensive income/(loss)	0.8	(1.2)	(0.4)
Balance at March 31, 2014	\$ (119.4)	\$ (34.9)	\$ (154.3)

**NOTE 15 RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS**

In July 2013, the FASB issued ASU 2013-11, Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists ( ASU 2013-11 ), which requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward. To the extent the tax benefit is not available at the reporting date under the governing tax law or if the entity does not intend to use the deferred tax asset for such

purpose, the unrecognized tax benefit should be presented as a liability and not combined with deferred tax assets. ASU 2013-11 is effective for annual periods, and interim periods within those years, beginning after December 15, 2013. The amendments are to be applied to all unrecognized tax benefits that exist as of the effective date and may be applied retrospectively to each prior reporting period presented. The implementation of the amended accounting guidance has not had a material impact on our consolidated financial statements.

**Table of Contents**

***NOTE 16 RELATED PARTY TRANSACTIONS***

Mr. Robert I. Paller has been a non-executive director of the Company since November 1, 2009. The Company has retained and continues to retain Smith, Gambrell & Russell, LLP ( SGR ), a law firm with which Mr. Paller holds a position. In the first three months of 2014 the Company incurred fees payable to SGR of \$0.1 million (2013 full year \$1.0 million). As at March 31, 2014, the amount due to SGR from the Company was \$0.1 million (December 31, 2013 \$0.2 million).

**Table of Contents****Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations for the Three Months Ended March 31, 2014**

This discussion should be read in conjunction with our unaudited interim consolidated financial statements and the notes thereto.

**CRITICAL ACCOUNTING ESTIMATES**

The policies and estimates that the Company considers the most critical in terms of complexity and subjectivity of assessment are those related to contingencies, environmental liabilities, pensions, deferred tax and uncertain income tax positions, goodwill, and other intangible assets (net of amortization) and property, plant and equipment. These policies have been discussed in the Company's 2013 Annual Report on Form 10-K.

**RESULTS OF OPERATIONS**

The following table provides operating income by reporting segment:

(in millions)	Three Months Ended March 31	
	2014	2013
<b>Net sales:</b>		
Fuel Specialties	\$ 164.2	\$ 140.0
Performance Chemicals	56.1	47.8
Octane Additives	0.4	11.6
	\$ 220.7	\$ 199.4
<b>Gross profit:</b>		
Fuel Specialties	\$ 52.0	\$ 47.0
Performance Chemicals	13.6	10.5
Octane Additives	0.1	6.3
	\$ 65.7	\$ 63.8
<b>Operating income:</b>		
Fuel Specialties	\$ 25.8	\$ 24.9
Performance Chemicals	6.5	5.0
Octane Additives	(1.2)	4.8
Pension credit/(charge)	(0.8)	(0.7)
Corporate costs	(12.1)	(11.5)
Restructuring charge	(0.2)	0.0
Impairment of Octane Additives segment goodwill	0.0	(0.3)
<b>Total operating income</b>	<b>\$ 18.0</b>	<b>\$ 22.2</b>



**Table of Contents**

(in millions, except ratios)	Three Months Ended			
	March 31			
	2014	2013	Change	
<b>Net sales:</b>				
Fuel Specialties	\$ 164.2	\$ 140.0	\$ 24.2	+17%
Performance Chemicals	56.1	47.8	8.3	+17%
Octane Additives	0.4	11.6	(11.2)	-97%
	\$ 220.7	\$ 199.4	\$ 21.3	+11%
<b>Gross profit:</b>				
Fuel Specialties	\$ 52.0	\$ 47.0	\$ 5.0	+11%
Performance Chemicals	13.6	10.5	3.1	+30%
Octane Additives	0.1	6.3	(6.2)	-98%
	\$ 65.7	\$ 63.8	\$ 1.9	+3%
<b>Gross margin (%):</b>				
Fuel Specialties	31.7	33.6	-1.9	
Performance Chemicals	24.2	22.0	+2.2	
Octane Additives	25.0	54.3	-29.3	
Aggregate	29.8	32.0	-2.2	
<b>Operating expenses:</b>				
Fuel Specialties	\$ (26.2)	\$ (22.1)	\$ (4.1)	+19%
Performance Chemicals	(7.1)	(5.5)	(1.6)	+29%
Octane Additives	(1.3)	(1.5)	0.2	-13%
Pension credit/(charge)	(0.8)	(0.7)	(0.1)	+14%
Corporate costs	(12.1)	(11.5)	(0.6)	+5%
	\$ (47.5)	\$ (41.3)	\$ (6.2)	+15%

**Fuel Specialties**

*Net sales:* the table below details the components which comprise the year on year change in net sales spread across the markets in which we operate:

Change (%)	Three Months Ended March 31, 2014				
	Americas	EMEA	ASPAC	Avtel	Total
Volume	+11	+3	-1	-13	+4
Price and product mix	0	+3	-16	-4	-1
Exchange rates	0	+4	0	0	+1
Acquisitions	+32	0	0	0	+13
	+43	+10	-17	-17	+17



**Table of Contents**

Americas saw an increase in volumes in the first quarter of 2014 as a result of higher demand, while acquisitions, relating to Bachman, generated additional sales compared to 2013. EMEA volumes increased from the prior year due to higher demand, while benefiting from an improved price and product mix. EMEA benefited from favorable exchange rates driven primarily by a strengthening of the European Union euro against the U.S. dollar. Volumes were marginally lower in ASPAC combined with an adverse price and product mix as a result of lower sales of higher margin products. Avtel volumes decreased due to the timing of shipments to customers as opposed to any change in the long-term outlook for that market, while the price and product mix was negatively impacted by an adverse customer mix.

*Gross margin:* the year on year decrease of 1.9% primarily reflected lower sales in our higher margin Avtel business compared to a strong comparative quarter in 2013; and by an adverse price and product mix in ASPAC.

*Operating expenses:* the year on year increase of 19%, or \$4.1 million, was due to \$5.3 million of additional costs for the Bachman businesses; offset by a \$1.1 million decrease in personnel-related compensation costs, primarily due to lower accruals for share-based compensation expense; and a \$0.1 million decrease in other expenses.

**Performance Chemicals**

*Net sales:* the table below details the components which comprise the year on year change in net sales spread across the markets in which we operate:

Change (%)	Three Months Ended March 31, 2014			
	Americas	EMEA	ASPAC	Total
Volume	-15	+5	+27	-1
Price and product mix	0	+2	-5	0
Exchange rates	+1	+4	+2	+2
Acquisitions	+35	0	0	+16
	+21	+11	+24	+17

Volumes in the Americas were lower, primarily due to lower volumes in Fragrance Ingredients and for an industrial product. Acquisitions in the Americas, relating to Chemsil and Chemtec, generated additional sales compared to 2013. Volumes in EMEA were higher than the prior year, primarily due to higher volumes in Personal Care, combined with an improved price and product mix. EMEA benefited from favorable exchange rates driven primarily by a strengthening of the European Union euro against the U.S. dollar. ASPAC volumes were significantly higher in Personal Care and Fragrance Ingredients although adversely impacted by higher sales of lower margin products. ASPAC benefited from favorable exchange rates against the U.S. dollar.

*Gross margin:* the year on year increase of 2.2% primarily reflected improved price and product mix in our Personal Care market together with higher margins in our Chemsil business, partly offset by adverse price and product mix in ASPAC.

*Operating expenses:* the year on year increase of 29%, or \$1.6 million, was primarily in respect of \$2.1 million of additional costs for our Chemsil and Chemtec businesses, partly offset by a \$0.5 million reduction in other costs including lower agents commission and lower personnel-related compensation driven by lower accruals for share-based compensation expense.



**Octane Additives**

*Net sales:* decreased by 97% with decreased volumes (down 94%), due to the timing of shipments and declining demand from major customers, and an adverse customer mix (down 2%), together with reduced revenue from our environmental remediation business (down 1%).

**Table of Contents**

*Gross margin:* the year on year decrease of 29.3% was principally due to lower manufacturing volumes.

*Operating expenses:* the year on year decrease of \$0.2 million was due to the efficient management of the cost base.

**Other Income Statement Captions**

*Pension credit/(charge):* is non-cash, and was a \$0.8 million net charge in 2014 compared to \$0.7 million net charge in 2013.

*Corporate costs:* the year on year increase of 5%, or \$0.6 million, primarily reflected \$0.9 million higher costs for amortization of the new information system platform; \$1.5 million provision for insurance claims within the group; \$0.4 million higher legal and other professional expenses; partly offset by \$2.2 million lower personnel-related compensation costs, primarily due to lower accruals for share-based compensation expense.

*Impairment of Octane Additives segment goodwill:* was \$0.0 million in 2014 and \$0.3 million in 2013.

*Other net income/(expense):* other net income of \$1.9 million primarily related to gains of \$1.5 million on translation of net assets denominated in non-functional currencies in our European businesses. In 2013, other net income of \$1.0 million primarily related to net foreign exchange gains on foreign currency forward exchange contracts.

*Interest expense, net:* was \$0.9 million in 2014 and \$0.3 million in 2013 due to the higher level of borrowing during 2014, used primarily to fund our acquisition activity.

*Income taxes:* the effective tax rate was 11.1% and 21.4% in 2014 and 2013, respectively. The adjusted effective tax rate, once adjusted for non-recurring items relating to the adjustment of income tax provisions, was 22.6% compared to 23.1% in the prior year. The 0.5% reduction was primarily due to the first quarter of 2014 benefiting to a minor extent from the positive impact of taxable profits in different geographical locations as compared to the first quarter of 2013. The Company believes that this adjusted effective tax rate, a non-GAAP financial measure, provides useful information to investors and may assist them in evaluating the Company's underlying performance and identifying operating trends. In addition, management uses this non-GAAP financial measure internally to evaluate the performance of the Company's operations and for planning and forecasting in subsequent periods.

(in millions)	Three Months Ended	
	March 31	
	2014	2013
Income before income taxes	\$ 19.0	\$ 22.9
Income taxes	\$ 2.1	\$ 4.9
Add back adjustment of income tax positions	2.2	0.4
	\$ 4.3	\$ 5.3
GAAP effective tax rate	11.1%	21.4%
Adjusted effective tax rate	22.6%	23.1%



**Table of Contents****LIQUIDITY AND FINANCIAL CONDITION****Working Capital**

The Company believes that adjusted working capital, a non-GAAP financial measure, (defined by the Company as trade and other accounts receivable, inventories, prepaid expenses, accounts payable and accrued liabilities rather than total current assets less total current liabilities) provides useful information to investors in evaluating the Company's underlying performance and identifying operating trends. Management uses this non-GAAP financial measure internally to allocate resources and evaluate the performance of the Company's operations. Items excluded from the adjusted working capital calculation are listed in the table below and represent factors which do not fluctuate in line with the day to day working capital needs of the business.

<b>(in millions)</b>	<b>March 31, 2014</b>	<b>December 31, 2013</b>
Total current assets	\$ 394.6	\$ 407.4
Total current liabilities	(127.0)	(155.6)
Working capital	267.6	251.8
Less cash and cash equivalents	(90.1)	(80.2)
Less short-term investments	(5.8)	(6.6)
Less current portion of deferred tax assets	(8.7)	(8.7)
Less prepaid income taxes	(3.4)	(11.4)
Add back current portion of long-term debt	5.4	5.3
Add back current portion of plant closure provisions	5.4	6.2
Add back current portion of unrecognized tax benefits	0.0	6.8
Add back current portion of deferred tax liabilities	0.2	0.2
Add back current portion of deferred income	0.3	0.3
Adjusted working capital	\$ 170.9	\$ 163.7

In 2014 our adjusted working capital increased by \$7.2 million, compared to a \$1.1 million decrease in the first quarter of 2013, primarily due to higher payments to external suppliers subsequent to the year end.

The \$13.8 million decrease in trade and other accounts receivable primarily reflects a decrease in our Octane Additives segment, with sales for the first quarter of 2014 being \$25 million lower than the fourth quarter of 2013. Days sales outstanding in our Fuel Specialties segment decreased from 49 days to 44 days, whilst they increased slightly from 51 days to 52 days in our Performance Chemicals segment.

The \$1.3 million increase in inventories is primarily due to increased inventories in our Octane Additives segment due to the timing of shipments expected early in the second quarter. Days sales in inventory in our Fuel Specialties segment remained unchanged at 79 days, whilst declining in our Performance Chemicals segment over the same period from 96 days to 83 days as the relatively high level of inventories at the year end was sold through.

Prepaid expenses decreased \$1.4 million from \$5.8 million to \$4.4 million, primarily related to the normal expensing of prepaid costs.



## **Table of Contents**

The \$21.1 million decrease in accounts payable and accrued liabilities was due to reductions across all our segments, primarily reflecting payments to external suppliers subsequent to the year end following our normally high sales in the fourth quarter, together with payments for personnel-related compensation. Creditor days in our Fuel Specialties segment decreased from 32 days to 30 days and in our Performance Chemicals segment decreased from 42 days to 26 days.

## **Operating Cash Flows**

We generated cash from operating activities of \$20.9 million in 2014 compared to \$17.9 million in 2013. Year over year cash from operating activities has been impacted by lower net income, higher cash outflows for our working capital requirements, and significant movements in taxes. In 2014 our working capital requirements increased by \$6.8 million, compared to a \$2.0 million increase in 2013.

## **Cash**

At March 31, 2014 and December 31, 2013 we had cash and cash equivalents of \$90.1 million and \$80.2 million, respectively, of which \$84.1 million and \$73.3 million, respectively, were held by non-U.S. subsidiaries principally in the United Kingdom. The Company is in a position to control whether or not to repatriate foreign earnings and intends to reinvest earnings to fund overseas subsidiaries. We currently do not expect to make a further repatriation in the foreseeable future and hence have not provided for future income taxes on the cash held by overseas subsidiaries. If circumstances were to change that would cause these earnings to be repatriated an additional U.S. tax liability could be incurred, and we continue to monitor this position.

## **Short-term investments**

At March 31, 2014 and December 31, 2013, we had short-term investments of \$5.8 million and \$6.6 million, respectively.

## **Debt**

At March 31, 2014, the Company had debt outstanding of \$134.0 million under its credit facility, a \$5.0 million promissory note and \$0.7 million of debt financing within our acquired Bachman businesses. The credit facility provides for borrowings by us of up to \$180 million until it expires on December 14, 2016 and may be drawn down in full in the U.S.. In addition, the Company can request an additional amount of up to \$20 million to be committed by the lenders.

## **Item 3 Quantitative and Qualitative Disclosures about Market Risk**

The Company uses floating rate debt to finance its global operations. The Company is subject to business risks inherent in non-U.S. activities, including political and economic uncertainty, import and export limitations, and market risk related to changes in interest rates and foreign currency exchange rates. The political and economic risks are mitigated by the stability of the countries in which the Company's largest operations are located. Credit limits, ongoing credit evaluation and account monitoring procedures are used to minimize bad debt risk. Collateral is not generally required.

The Company uses derivatives, including interest rate swaps, commodity swaps and foreign currency forward exchange contracts, in the normal course of business to manage market risks. The derivatives used in hedging

activities are considered risk management tools and are not used for trading purposes. In addition, the Company enters into derivative instruments with a diversified group of major financial institutions in order to manage the exposure to non-performance of such instruments. The Company's objective in managing the exposure to changes in interest rates is to limit the impact of such changes on earnings and cash flows and to lower overall borrowing costs. The Company's objective in managing the exposure to changes in foreign currency exchange rates is to reduce volatility on earnings and cash flows associated with such changes.

## **Table of Contents**

The Company offers fixed prices for some long-term sales contracts. As manufacturing and raw material costs are subject to variability the Company uses commodity swaps to hedge the cost of some raw materials thus reducing volatility on earnings and cash flows. The derivatives are considered risk management tools and are not used for trading purposes. The Company's objective is to manage its exposure to fluctuating costs of raw materials.

The Company's exposure to market risk has been discussed in the Company's 2013 Annual Report on Form 10-K and there have been no significant changes since that time.

### **Item 4 Controls and Procedures** **Evaluation of Disclosure Controls and Procedures**

Based on an evaluation carried out as of the end of the period covered by this report, under the supervision and with the participation of our management, our Chief Executive Officer and our Chief Financial Officer concluded that the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) were effective as of March 31, 2014.

### **Changes in Internal Controls over Financial Reporting**

The Company is continuously seeking to improve the efficiency and effectiveness of its operations and of its internal controls. This is intended to result in refinements to processes throughout the Company. There were no changes in the Company's internal control over financial reporting, which were identified in connection with the evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Securities Exchange Act of 1934, during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

## **PART II OTHER INFORMATION**

### **Item 1 Legal Proceedings** **Jalal Bezee Mejel Al-Gaood & Partner litigation**

On September 19, 2012, a claim was filed in the High Court of Justice in the United Kingdom by Jalal Bezee Mejel Al-Gaood & Partner and Future Agencies Company Limited (collectively "JAG") against the Company, Innospec Limited and a former employee of Innospec Limited. The Company believes JAG was the former Iraq distributor for Afton Chemicals Limited, a subsidiary of NewMarket Corporation, from at least 2005 until termination of that relationship in 2010. The stated claim, inclusive of costs and expenses, is for up to \$42.3 million and relates to alleged loss of profits for JAG's business in Iraq between 2004 and 2010. The Company believes that the allegations in the JAG claim are without merit and intends to defend vigorously its interests.



**Table of Contents**

**Other legal matters**

While we are involved from time to time in claims and legal proceedings that result from, and are incidental to, the conduct of our business including business and commercial litigation, employee and product liability claims, there are no other material pending legal proceedings to which the Company or any of its subsidiaries is a party, or of which any of their property is subject. It is possible, however, that an adverse resolution of an unexpectedly large number of such individual claims or proceedings could in the aggregate have a material adverse effect on results of operations for a particular year or quarter.

**Item 1A Risk Factors**

Information regarding risk factors appears in Item 1A of the Company's 2013 Annual Report on Form 10-K and, in management's view, there have been no material changes in the risk factors facing the Company since that time.

**Item 2 Unregistered Sales of Equity Securities and Use of Proceeds**

There were no unregistered sales of equity securities, nor any purchases of equity securities by the issuer in the quarter ended March 31, 2014.

**Item 3 Defaults Upon Senior Securities**

None.

**Item 4 Mine Safety Disclosures**

Not applicable.

**Item 5 Other Information**

None.

**Item 6 Exhibits**

10.1 Form of Indemnification Agreement for individual who is an officer (1)

10.2 Form of Indemnification Agreement for individual who is a director (1)

10.3 Form of Indemnification Agreement for individual who is an officer and director (1)

10.4 Employment contract for Brian Watt \*

10.5 Innospec Inc. 2014 Long-Term Incentive Plan \*

31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

**Table of Contents**

32.1 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101 XBRL Instance Document and Related Items.

(1) Incorporated by reference to the Form 8-K previously filed on February 27, 2014.

\* Denotes a management contract or compensatory plan.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 7, 2014

By */s/* PATRICK S. WILLIAMS  
**Patrick S. Williams**  
**President and Chief Executive Officer**

Date: May 7, 2014

By */s/* IAN P. CLEMINSON  
**Ian P. Cleminson**  
**Executive Vice President and Chief Financial Officer**